Flerie has received approval for its merger with Lipum AB, positioning itself for enhanced growth in the life sciences sector.

Information on the Target

The proposed merger between Flerie and Lipum AB (publ) has been officially approved by an extraordinary general meeting. This approval pertains to the merger plan dated November 18, 2025, which has been jointly adopted by the boards of both Flerie and Lipum. The merger plan was registered with the Swedish Companies Registration Office on November 19, 2025, and announced on November 21, 2025. The merger will occur through an absorption process, with Flerie as the acquiring company and Lipum as the transferring company. Following the merger, Lipum’s operations will be incorporated into a new subsidiary of Flerie's wholly owned subsidiary, Flerie Invest AB.

According to the merger plan, the exchange ratio for the merger consideration has been established as 2.4421 shares of Lipum to one (1) new ordinary share of Flerie. The merger is anticipated to be registered by the Swedish Companies Registration Office by the end of the first quarter of 2026, resulting in the dissolution of Lipum, whereby all of Lipum’s assets and liabilities will be transferred to Flerie. Accounting for the merger consideration will occur after the official registration of the merger.

Industry Overview

Sweden's Life Sciences sector is recognized as a powerful driver of innovation and economic growth, comprising a robust landscape of biotech, pharma, and medical technology companies. The country boasts a well-established research infrastructure and a skilled workforce